The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•28 February 2026•

1 min read

Immunic Secures $400 Million to Fund Late-Stage Multiple Sclerosis Trials

Key Facts

1Immunic secured up to $400 million in a private placement to support late-stage trials for its multiple sclerosis treatment.

2$200 million has already been received, with the remainder available in a second tranche.

Immunic Inc (NASDAQ: IMUX) has successfully secured up to $400 million through a private placement to advance its clinical pipeline. The biotechnology company confirmed that $200 million has already been received, with the remaining balance accessible in a second tranche. These funds are specifically earmarked to complete late-stage trials for vidofludimus calcium, a promising treatment for multiple sclerosis. Beyond clinical milestones, the capital injection will support preparations for a potential commercial launch of the drug. CEO Dr. Daniel Vitt emphasized that this financing provides the necessary runway to reach critical Phase 3 objectives. This significant capital raise reduces financial risk for the company as it approaches pivotal data readouts.